Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy

Journal of Cardiology

Volumn 57, Issue 2, 2011, Pages 194-201

  Yamamoto, Koichiro ^a   Hokimoto, Seiji ^a   Chitose, Tadasuke ^a   Morita, Kazunori ^b   Ono, Takamichi ^a   Kaikita, Koichi ^a   Tsujita, Kenichi ^a   Abe, Tomohide ^b   Deguchi, Mariko ^b   Miyagawa, Haruna ^b   Saruwatari, Junji ^b   Sumida, Hitoshi ^a   Sugiyama, Seigo ^a   Nakagawa, Kazuko ^b   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Coronary heart disease; Genetics; Pharmacology; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CLOPIDOGREL; CYTOCHROME P450 2C19;

AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY STENT; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HEART DEATH; HEART INFARCTION; HOMOZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; JAPANESE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; STROKE; THROMBOCYTE AGGREGATION; WILD TYPE;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CORONARY DISEASE; ENDOVASCULAR PROCEDURES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; STENTS; TICLOPIDINE;

EID: 79951943784     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.10.007     Document Type: Article

References (24)

1. King S.B., Smith S.C., Hirshfeld J.W., Jacobs A.K., Morrison D.A., Williams D.O., Feldman T.E., Kern M.J., O'Neill W.W., Schaff H.V., Whitlow P.L., Adams C.D., Anderson J.L., Buller C.E., Creager M.A., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008, 51:172-209.
2. Kushner F.G., Hand M., Smith S.C., King S.B., Anderson J.L., Antman E.M., Bailey S.R., Bates E.R., Blankenship J.C., Casey D.E., Green L.A., Hochman J.S., Jacobs A.K., Krumholz H.M., Morrison D.A., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 Guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2009, 120:2271-2306.
3. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., Collins R., Liu L.S. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
4. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., Claeys M.J., Cools F., Hill K.A., Skene A.M., McCabe C.H., Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179-1189.
5. Ang L., Palakodeti V., Khalid A., Tsimikas S., Idrees Z., Tran P., Clopton P., Zafar N., Bromberg-Marin G., Keramati S., Mahmud E. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008, 52:1052-1059.
6. Geisler T., Grass D., Bigalke B., Stellos K., Drosch T., Dietz K., Herdeg C., Gawaz M. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008, 6:54-61.
7. Serebruany V., Cherala G., Williams C., Surigin S., Booze C., Kuliczkowski W., Atar D. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance" Am Heart J 2009, 158:925-932.
8. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., Sabatine M.S. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
9. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Meneveau N., Steg P.G., Ferrieres J., Danchin N., Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
10. Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., Payot L., Brugier D., Cayla G., Beygui F., Bensimon G., Funck-Brentano C., Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
11. Trenk D., Hochholzer W., Fromm M.F., Chialda L.E., Pahl A., Valina C.M., Stratz C., Schmiebusch P., Bestehorn H.P., Buttner H.J., Neumann F.J. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008, 51:1925-1934.
12. De Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994, 46:594-598.
13. Kubota T., Chiba K., Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996, 60:661-666.
14. Richards B., Skoletsky J., Shuber A.P., Balfour R., Stern R.C., Dorkin H.L., Parad R.B., Witt D., Klinger K.W. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993, 2:159-163.
15. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994, 269:15419-15422.
16. Angiolillo D.J. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009, 103:27A-34A.
17. Angiolillo D.J., Bernardo E., Sabate M., Jimenez-Quevedo P., Costa M.A., Palazuelos J., Hernandez-Antolin R., Moreno R., Escaned J., Alfonso F., Banuelos C., Guzman L.A., Bass T.A., Macaya C., Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007, 50:1541-1547.
18. Samara W.M., Bliden K.P., Tantry U.S., Gurbel P.A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005, 115:89-94.
19. Jinnai T., Horiuchi H., Makiyama T., Tazaki J., Tada T., Akao M., Ono K., Hoshino K., Naruse Y., Takahashi K., Watanabe H., Kita T., Kimura T. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 2009, 73:1498-1503.
20. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007, 50:1822-1834.
21. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., van Domburg R.T., Hess O.M., Boersma E., Meier B., Windecker S., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
22. Aoki J., Lansky A.J., Mehran R., Moses J., Bertrand M.E., McLaurin B.T., Cox D.A., Lincoff A.M., Ohman E.M., White H.D., Parise H., Leon M.B., Stone G.W. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2009, 119:687-698.
23. Kimura T., Morimoto T., Nakagawa Y., Tamura T., Kadota K., Yasumoto H., Nishikawa H., Hiasa Y., Muramatsu T., Meguro T., Inoue N., Honda H., Hayashi Y., Miyazaki S., Oshima S., et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009, 119:987-995.
24. Geisler T., Zurn C., Simonenko R., Rapin M., Kraibooj H., Kilias A., Bigalke B., Stellos K., Schwab M., May A.E., Herdeg C., Gawaz M. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010, 31:59-66.